Theriva Biologics (NYSEAMERICAN:TOVX) Releases Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) posted its earnings results on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, FiscalAI reports.

Theriva Biologics Stock Performance

NYSEAMERICAN TOVX opened at $0.23 on Wednesday. The stock has a market capitalization of $7.90 million, a price-to-earnings ratio of -0.01 and a beta of 1.11. The stock has a 50-day moving average of $0.24 and a 200 day moving average of $0.24. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11. Theriva Biologics has a twelve month low of $0.16 and a twelve month high of $0.86.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Theriva Biologics stock. Geode Capital Management LLC boosted its stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 at the end of the most recent quarter. Institutional investors own 6.17% of the company’s stock.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.